TheraVida is dedicated to the development of new therapies to improve the lives of patients with hyperhidrosis.

Using a unique and patent-protected combination drug technology, we are developing a pharmaceutical product with an improved tolerability profile relative to existing therapies. Our technology has been shown in initial clinical trials to deliver this benefit without sacrificing efficacy.

Our lead combination drug product, THVD-102, has successfully completed a phase 2 human study for the treatment of primary focal hyperhidrosis.